2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 479

Protein Carbamylation Is Induced By Activated Neutrophil: Ex Vivo Analysis
Abstract Number: 1411

Protein Tyrosine Phosphatase Non-Receptor 22 / C-Src Tyrosine Kinase Complex Down-Regulated in Patients with Rheumatoid Arthritis
Abstract Number: 2123

Protein-Losing Enteropathy in Patients with Systemic Autoimmune Diseases: Characterization of 263 Cases (GEAS-SEMI Spanish Cohort)
Abstract Number: 769

Proteomic Analysis of Human Fibroblasts in Systemic Sclerosis Reinforces the Role of Transforming Growth Factor-ß and Points Toward Epidermal Growth Factor Receptor / Phosphatidylinositol 3 Kinase Pathway Inhibition
Abstract Number: 765

Proteomic Analysis of Scleroderma Associated Joint Disease
Abstract Number: 2626

Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics and Outcomes
Abstract Number: 2060

Pseudogout Among Patients Fulfilling a Billing Code Algorithm for Calcium Pyrophosphate Deposition Disease (CPPD)
Abstract Number: 2544

Psoriatic Arthritis Impact of Disease (PSAID12) in Early Psoriatic Arthritis: Pain As One of the Main Determinants of Disease Impact
Abstract Number: 335

Psoriatic Arthritis Patients Who Attain a Very Low Disease Activity State Have a Minimal Impact of the Disease on Their Lives
Abstract Number: 254

Psoriatic Arthritis Sonographic Enthesitis Scores – Systematic Review of the Literature
Abstract Number: 1807

Psychometric Evaluation of the Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) in Inflammatory Arthritis
Abstract Number: 352

Psychometric Features of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients with Rheumatoid Arthritis (RA): Preliminary Results from an Online Patient Community
Abstract Number: 1062

Ptpn22 Regulates Synovial Slam Family Receptor Expression during Toll-like Receptor-Driven Suppression of Inflammatory Arthritis
Abstract Number: 991

Publication Timeliness of the Randomized Controlled Trials of Drug Therapy for Inflammatory Arthritis
Abstract Number: 529

Pulmonary Involvement in Our Patients with Rheumatoid Arthritis Under Biological Therapy: A Tertiary Hospital Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].